Kane Biotech Inc., a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has successfully developed the manufacturing process and completed the pilot scale production of the Company’s StrixNB Pet Oral Care product. StrixNB is a patent pending oral care product comprising a unique synergistic combination of food grade ingredients that have both the synergistic antimicrobial and antibiofilm activity against oral bacteria.
Four separate pilot manufacturing runs were conducted during the scale up following the required quality control procedures. The successful pilot production confirms the scale up feasibility for commercial production of StrixNB at a very favourable cost of goods which moves the Company closer to market launch.
The pilot scale manufacturing was conducted by the Richardson Centre for Functional Foods and Nutraceuticals (RCFFN) in Winnipeg, Manitoba. The RCFFN has unique capability, equipment and expertise in assisting companies moving their manufacturing process from the lab bench to commercial scale up.
“Pilot manufacturing and scalable production is an important step and confirms that we can scale up production to meet commercial volumes of our scientifically formulated product, as we prepare for a market entry”, stated Gord Froehlich, President and CEO of Kane Biotech.
About The Richardson Centre for Functional Foods and Nutraceuticals.
The Richardson Centre for Functional Foods and Nutraceuticals is a bioprocessing and product development facility dedicated to the discussion, discovery, and development of functional foods and nutraceuticals. The Centre is available to agri-food, natural health product, and pharmaceutical industries to determine structure, function, efficacy, and safety of functional foods and nutraceuticals, as well as to evaluate products in controlled animal and human studies for potential health claims and palatability. The Centre has expertise and equipment to move from prototype to pilot plant to ensure processes are fully scalable and optimal for commercial activity.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.